國立虎尾科技大學 |

Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study./
Author:	Patkar, Anuprita D.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2005,
Description:	160 p.
Notes:	Source: Dissertation Abstracts International, Volume: 66-11, Section: B, page: 5923.
Contained By:	Dissertation Abstracts International66-11B.
Subject:	Pharmaceutical sciences. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3196517
ISBN:	9780542424434

Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study.
Patkar, Anuprita D.

Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study. - Ann Arbor : ProQuest Dissertations & Theses, 2005 - 160 p.

Source: Dissertation Abstracts International, Volume: 66-11, Section: B, page: 5923.

Thesis (Ph.D.)--Virginia Commonwealth University, 2005.

The American Medical Association (AMA) has estimated that as many as 40 percent of all prescriptions are issued for off label use. Off-label prescribing is considered to be clinically beneficial and rational in certain life-threatening situations. However, off-label use can pose risks to patients in terms of adverse drug events as well as contribute to rising pharmaceutical costs. The anti-anemic drugs erythropoietin and darbepoetin are costly, and there are significant off-label uses for these drugs some of which are not supported with clinical evidence, hence were selected as study drugs. Our study goals included quantification of the prevalence rate and appropriateness of off label use of erythropoietin and darbepoetin across U.S. hospitals, and identification of possible predictors of off-label use from the domains of patient characteristics, physician specialty, hospital characteristics and drug characteristics.

ISBN: 9780542424434Subjects--Topical Terms:

1180569
Pharmaceutical sciences.

Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study.
LDR:03383nam a2200313 4500 001 931749
005 20190716101637.5
008 190815s2005 ||||||||||||||||| ||eng d
020 $a 9780542424434
035 $a (MiAaPQ)AAI3196517
035 $a AAI3196517
040 $a MiAaPQ $c MiAaPQ
100 1 $a Patkar, Anuprita D. $3 1213966
245 1 0 $a Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2005
300 $a 160 p.
500 $a Source: Dissertation Abstracts International, Volume: 66-11, Section: B, page: 5923.
500 $a Director: David A. Holdford.
502 $a Thesis (Ph.D.)--Virginia Commonwealth University, 2005.
520 $a The American Medical Association (AMA) has estimated that as many as 40 percent of all prescriptions are issued for off label use. Off-label prescribing is considered to be clinically beneficial and rational in certain life-threatening situations. However, off-label use can pose risks to patients in terms of adverse drug events as well as contribute to rising pharmaceutical costs. The anti-anemic drugs erythropoietin and darbepoetin are costly, and there are significant off-label uses for these drugs some of which are not supported with clinical evidence, hence were selected as study drugs. Our study goals included quantification of the prevalence rate and appropriateness of off label use of erythropoietin and darbepoetin across U.S. hospitals, and identification of possible predictors of off-label use from the domains of patient characteristics, physician specialty, hospital characteristics and drug characteristics.
520 $a To address the research questions we performed a retrospective review of 464,834 discharged patients across 515 hospitals who have received erythropoietin and darbepoetin from the time periods between 2001 and 2004. The data was supplied by SolucientRTM. The uses of the two drugs have been categorized using an evidence-based medicine framework that classifies them into: (a) on-label use (approved by the FDA), (b) off-label use supported (use not approved by FDA but there is strong clinical evidence supporting off-label use), and (c) off-label use unsupported (lack of clinical evidence). A multinomial logistic regression model clustered by hospitals was conducted to determine predictors of off-label use.
520 $a The results of this study revealed that more than half of the utilization of the two erythropoietic drugs is for off-label purposes, the majority of which is supported with evidence. Among the covariates, physician specialty, patient age group, race, drug coverage and length of hospital stay were significant (0.05 level) predictors of off-label use (supported and unsupported) relative to on-label. It is useful to understand the extent and appropriateness of off-label utilization in order to ensure safe and cost-effective use in patients. The availability of empirically derived knowledge on the national level could precipitate the promulgation of more meaningful post-marketing surveillance measures.
590 $a School code: 2383.
650 4 $a Pharmaceutical sciences. $3 1180569
650 4 $a Medicine. $3 644133
690 $a 0572
690 $a 0564
710 2 $a Virginia Commonwealth University. $3 1213967
773 0 $t Dissertation Abstracts International $g 66-11B.
790 $a 2383
791 $a Ph.D.
792 $a 2005
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3196517